Convergence
in oncology summit

September 24-25 2020, Digitally Streamed from Lausanne

ABOUT

The Convergence in Oncology Summit is an international annual assembly of industry leaders, entrepreneurs, and investors active in the field of Oncology to debate and explore synergies that can accelerate the development of the most promising solutions in the field.

From diagnostics to therapeutics, rapid change in technology innovation modifies the landscape faster than any organizations can keep up with. Convergence of technologies from mature and emerging sectors are creating new opportunities that can significantly accelerate disruptive solutions that benefit patients globally.

The principal aim of this Summit is to promote development of new solutions through convergence and sharing of opportunities in the field of Oncology. The Summit is organized by professionals for professionals and we look forward to welcoming you digitally on our platform, for networking and sharing of knowledge among industry leaders, entrepreneurs, academics and investors.

Due to the current worldwide health situation, we will hold the meeting only digitally for the 2020 edition.

More information

Industry Leaders Entrepreneurs Investors
• Panel discussions • Company presentations • Investment outlook
Digitization    Prevention    Diagnostics    Therapeutics

Programme 2020

The Summit is organized around eight consecutive plenary panel sessions over two days.

13.30 - 14.00 CET
Official Opening
Brian Hashemi , Salus Partners SA
Nasri Nahas, Biopôle SA
Raphael Conz, Economic Promotion Manager at SPEI, Vaud
14.00 - 15.30 CET
Translational Medicine: Immuno-oncology
Lana Kandalaft, Department of oncology UNIL CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research Lausanne
Ana Cerdeira, Molecular Partners
Jing Watnick, Vigeo Therapeutics
Michele De Palma, EPFL
Freddy Radtke, EPFL
Christopher Nicodemus, AIT Strategies (Franconia, NH USA)
15.40 - 17.10 CET
Next Generation Diagnostics in Oncology: The Promise of the OMICS Age
Miro Venturi
Giulio Superti Furga, Medical University of Vienna
Massimo Bocchi, CellPly Srl
Christian Ruiz, University of Basel
Alexandra Vallon-Eberhard, Roche Diagnostics
17.20 - 18.50 CET
From Data to Decision: Applied Artificial Intelligence in Oncology
Robert Murphy, Carnegie Mellon University
Maryellen Giger, The University of Chicago
Ron Alfa, Recursion Pharmaceuticals
Anant Madabhushi, Case Western Reserve University
Sahar Hosseinian, Novigenix SA
14.00 - 15.30 CET
CAR-T Cell Therapy: Challenges and Opportunities
Georges Coukos, Department of oncology UNIL CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research Lausanne
Raphaël Stadelmann, Service d’hématologie, CHUV, Lausanne
Jens Hasskarl, Celgene a BMS Company
Caroline Arber-Barth, Department of oncology UNIL CHUV , Ludwig Institute for Cancer Research Lausanne, University of Lausanne and Lausanne University Hospital
Li Tang, EPFL
Dorothea Ledergerber, Novartis
16.00 - 17.30 CET
Health Economics & Access to Innovation: What Does It Mean for Patients post COVID-19?
Herb Riband, InnAxx Consulting
Christina Rångemark Åkerman, Dell Medical School at the University of Texas
Bettina Ryll, Melanoma Patient Network Europe
Titta Rosvall-Puplett, Bristol Myers Squibb (BMS)
Kolleen Kennedy, Varian Medical Systems
18.00 - 19.30 CET
Convergence for Better Health Outcomes: Connecting the Dots & Salus Award
William Burns, Molecular Partners
Lana Kandalaft, Department of oncology UNIL CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research Lausanne
Miro Venturi
Dorothea Ledergerber, Novartis
Robert Murphy, Carnegie Mellon University
Herb Riband, InnAxx Consulting
Brian Hashemi , Salus Partners SA
Antoine Papiernik, Sofinnova Partners

Speakers


2020
Ron Alfa
Recursion Pharmaceuticals
2020
Caroline Arber-Barth
Department of oncology UNIL CHUV , Ludwig Institute for Cancer Research Lausanne, University of Lausanne and Lausanne University Hospital
2020
Massimo Bocchi
CellPly Srl
2020
William Burns
Molecular Partners
20192020
Ana Cerdeira
Molecular Partners
2020
Raphael Conz
Economic Promotion Manager at SPEI, Vaud
201820192020
Georges Coukos
Department of oncology UNIL CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research Lausanne
2020
Michele De Palma
EPFL
2020
Maryellen Giger
The University of Chicago
2020
Brian Hashemi
Salus Partners SA
202020192018
Jens Hasskarl
Celgene a BMS Company
2020
Sahar Hosseinian
Novigenix SA
2020
Lana Kandalaft
Department of oncology UNIL CHUV, Lausanne University Hospital, Ludwig Institute for Cancer Research Lausanne
20182020
Kolleen Kennedy
Varian Medical Systems
2020
Dorothea Ledergerber
Novartis
2020
Anant Madabhushi
Case Western Reserve University
2020
Robert Murphy
Carnegie Mellon University
2020
Nasri Nahas
Biopôle SA
201820192020
Christopher Nicodemus
AIT Strategies (Franconia, NH USA)
2020
Antoine Papiernik
Sofinnova Partners
2020
Freddy Radtke
EPFL
2020
Christina Rångemark Åkerman
Dell Medical School at the University of Texas
2020
Herb Riband
InnAxx Consulting
20192020
Titta Rosvall-Puplett
Bristol Myers Squibb (BMS)
2020
Christian Ruiz
University of Basel
2020
Bettina Ryll
Melanoma Patient Network Europe
2020
Raphaël Stadelmann
Service d’hématologie, CHUV, Lausanne
2020
Giulio Superti Furga
Medical University of Vienna
2020
Li Tang
EPFL
2020
Alexandra Vallon-Eberhard
Roche Diagnostics
2020
Miro Venturi
20192020
Jing Watnick
Vigeo Therapeutics
2020

Videos highlights

«When talking about Oncology, time is of essence and shortening. The only option we have left today is to converge and work together to speed up oncology research.» Nasri Nahas, CEO Biopôle

Keep me posted

Subscribe our contact list to receive updates about the Convergence in Oncology Summit.